LT4285902T - Pagerinta rūgštinė alfa-gliukozidazė pompe ligos gydymui - Google Patents

Pagerinta rūgštinė alfa-gliukozidazė pompe ligos gydymui

Info

Publication number
LT4285902T
LT4285902T LTEP23188938.7T LT23188938T LT4285902T LT 4285902 T LT4285902 T LT 4285902T LT 23188938 T LT23188938 T LT 23188938T LT 4285902 T LT4285902 T LT 4285902T
Authority
LT
Lithuania
Prior art keywords
glucosidase
treatment
acid alpha
pompe disease
augmented
Prior art date
Application number
LTEP23188938.7T
Other languages
English (en)
Inventor
Hung V. Do
Richie Khanna
Russell GOTSCHALL
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of LT4285902T publication Critical patent/LT4285902T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP23188938.7T 2015-12-30 2016-12-29 Pagerinta rūgštinė alfa-gliukozidazė pompe ligos gydymui LT4285902T (lt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08

Publications (1)

Publication Number Publication Date
LT4285902T true LT4285902T (lt) 2026-02-25

Family

ID=60186557

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP21174249.9T LT3957320T (lt) 2015-12-30 2016-12-29 Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui
LTEP16826898.5T LT3397273T (lt) 2015-12-30 2016-12-29 Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui
LTEP23188938.7T LT4285902T (lt) 2015-12-30 2016-12-29 Pagerinta rūgštinė alfa-gliukozidazė pompe ligos gydymui

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP21174249.9T LT3957320T (lt) 2015-12-30 2016-12-29 Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui
LTEP16826898.5T LT3397273T (lt) 2015-12-30 2016-12-29 Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui

Country Status (16)

Country Link
EP (4) EP3957320B1 (lt)
CN (1) CN108472340A (lt)
CY (1) CY1124637T1 (lt)
DK (3) DK4285902T3 (lt)
ES (2) ES2965190T3 (lt)
FI (2) FI4285902T3 (lt)
HK (1) HK1253014A1 (lt)
HR (3) HRP20210894T1 (lt)
HU (2) HUE064049T2 (lt)
LT (3) LT3957320T (lt)
PL (2) PL3957320T3 (lt)
PT (3) PT3397273T (lt)
RS (2) RS62212B1 (lt)
SI (2) SI3957320T1 (lt)
SM (3) SMT202600054T1 (lt)
TW (3) TW202506173A (lt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
HUE033381T2 (en) 2003-01-31 2017-11-28 Mount Sinai School Of Medicine Of New York Univ Combination therapy for the treatment of protein deficiency disorders
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
EP1896083B1 (en) 2005-05-17 2016-03-02 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
PL2252313T3 (pl) 2008-02-12 2015-09-30 Amicus Therapeutics Inc Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi
US20110070643A1 (en) * 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
SMT202100136T1 (it) 2012-05-03 2021-05-07 Amicus Therapeutics Inc Regimi posologici per il trattamento della malattia di pompe
CA2917995C (en) 2012-07-17 2021-01-26 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
PE20170906A1 (es) * 2014-09-30 2017-07-12 Amicus Therapeutics Inc Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados

Also Published As

Publication number Publication date
EP3957320A1 (en) 2022-02-23
TWI849380B (zh) 2024-07-21
EP3957320B1 (en) 2023-08-23
EP4706779A2 (en) 2026-03-11
SI3397273T1 (sl) 2021-11-30
FI4285902T3 (fi) 2026-02-17
DK3957320T3 (da) 2023-11-27
SMT202300412T1 (it) 2024-01-10
FI3957320T3 (fi) 2023-11-23
EP3397273A1 (en) 2018-11-07
TW202506173A (zh) 2025-02-16
CN108472340A (zh) 2018-08-31
PT4285902T (pt) 2026-02-10
PT3397273T (pt) 2021-08-09
HRP20260120T1 (hr) 2026-03-13
DK3397273T3 (da) 2021-08-09
DK4285902T3 (da) 2026-02-16
TW202245831A (zh) 2022-12-01
DK3957320T5 (da) 2024-08-05
EP3397273B1 (en) 2021-05-19
SMT202600054T1 (it) 2026-03-09
EP4285902B1 (en) 2025-11-19
HK1253014A1 (zh) 2019-06-06
EP4285902A2 (en) 2023-12-06
SI3957320T1 (sl) 2024-01-31
HRP20210894T1 (hr) 2021-07-23
LT3957320T (lt) 2023-12-11
PL3957320T3 (pl) 2024-02-19
ES2965190T3 (es) 2024-04-11
SMT202100452T1 (it) 2021-09-14
TW201726163A (zh) 2017-08-01
HUE064049T2 (hu) 2024-02-28
LT3397273T (lt) 2021-06-25
PL3397273T3 (pl) 2021-12-06
HUE054733T2 (hu) 2021-09-28
ES2883844T3 (es) 2021-12-09
EP4285902A3 (en) 2024-02-21
CY1124637T1 (el) 2022-07-22
PT3957320T (pt) 2023-11-23
RS62212B1 (sr) 2021-09-30
HRP20231465T1 (hr) 2024-03-01
RS64843B1 (sr) 2023-12-29
TWI753874B (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
IL325298A (en) Improved acid alpha-glucosidase for the treatment of Pompe disease
IL259133A (en) Jamkaban combinations for the treatment of cardiovascular disease
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
IL253945A0 (en) kdm1a inhibitors to treat the disease
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
ZA201907552B (en) Recombinant human acid alpha-glucosidase
IL255506A (en) A method for treating a neurological disease
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
EP3310377A4 (en) Method of treating crohn's disease
IL253726A0 (en) Preparations for the treatment of inflammatory diseases related to uric acid
GB201515244D0 (en) Treatment of inflammatory disease or condition
SI3397273T1 (sl) Dopolnjena kisla alfa glukozidaza za zdravljenje Pompejeve bolezni
GB201504413D0 (en) Treatment of disease
GB201621398D0 (en) Treatment of emt-associated disease
AU2015902286A0 (en) Method Of Treating Crohn's Disease
HK1259743A1 (en) Gemcabene combinations for the treatment of cardiovascular disease
AU2015902358A0 (en) Treatment of inflammatory disease